Franz-Werner Haas (Christoph Schmidt/picture-alliance/dpa/AP Images)
July 20, 2023 05:00 AM EDT
Deals
Bioregnum

A small Swiss biotech tack­les a huge glob­al health is­sue with a hand­off from GSK. But can it make any mon­ey from it?

Dur­ing the glob­al pan­dem­ic, we got a good look at how a new tech­nol­o­gy can trans­form the vac­cines mar­ket and earn bil­lions of dol­lars in …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times